CJC-1295 (no DAC) + Ipamorelin vs Tesamorelin

Name: CJC-1295 (no DAC) + Ipamorelin vs Tesamorelin
Published: 2026-10-23

Updated Oct 23, 202610 sources

Key differences

1Tesamorelin plus ipamorelin pairs a GHRH analog that has Phase 3 visceral-fat data with the same GHRP. CJC-1295 no DAC has no human data at all.

Facts from each record, in the same words as their own pages.

CJC-1295 (no DAC) + Ipamorelin and Tesamorelin side by side
	CJC-1295 (no DAC) + Ipamorelin	Tesamorelin
Category	GH axis	GH axis
Evidence	No human trials	Strong human trials
FDA status	Not FDA approvedRegulatory	FDA approved as Egrifta +2Regulatory
WADA	Prohibited	Prohibited
Half-life	Ipamorelin: about 2 hours after IV dosing. CJC-1295 no DAC: about 30 minutes per guides, never measured in humans.Competitor guide	8 minutes (Egrifta SV) and 11 minutes (Egrifta WR) in healthy subjects. Older figures for the original formulation are 26 to 38 minutes.Clinical study
Routes	Subcutaneous injection	Subcutaneous injection
Reported doses	100 to 400 mcg (subcutaneous injection) 100 to 500 mcg (subcutaneous injection)	1 to 2 mg (subcutaneous injection) 125 to 1,000 mcg (subcutaneous injection)
Most cited frequency	Once daily, before bed	Once daily
Vial sizes	10 mgCompetitor guide	2 mg, 5 mg, 10 mg, 20 mgCompetitor guide
Mixed vial keeps	Fridge, 2 to 8 °C.Competitor guide	Egrifta SV: use right after mixing and discard the rest.Competitor guide
Protocols on file	8	11

Doses shown are what sources report, labelled by origin. Not medical advice.

10 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.